A phase 2 study evaluated the efficacy and safety of adding pembrolizumab to trimodal therapy as a bladder-sparing approach for muscle-invasive bladder cancer (MIBC).
The company reported that its drug candidate, also known as zoci, achieved a 62.5% confirmed intracranial response rate at the 1.6 mg/kg dose level among 16 patients in an ongoing global Phase 1 trial ...
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy ...
Zai Lab Limited today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and robust intracranial ...
Everyday Health on MSN
Tips for managing metastatic bladder cancer treatment side effects
Learn expert-backed tips for lessening the negative effects of metastatic bladder cancer treatment.
Stifel on Thursday initiated coverage on Immunic Inc. IMUX, a late-stage biotechnology company developing oral therapies for ...
News from around the world of breast cancer research, legislation, and patient information from the editors at Breastcancer.org.
Bladder cancer trials of antibody-drug conjugates may change the standard for neoadjuvant therapy away from dependence on cisplatin chemotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results